Get started
Author

Susan Flynn

Observed name: Flynn, Susan
Institution: Genentech
OpenAlex ID: A5113671837
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
2018 · Marcin Kowanetz, Wei Zou, et al. · Proceedings of the National Academy of Sciences · 235
OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
2017 · Marcin Kowanetz, Wei Zou, et al. · Journal of Thoracic Oncology · 86
PDF
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Michael Fehlings, Suchit Jhunjhunwala, et al. · Journal for ImmunoTherapy of Cancer · 85
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
2021 · Namrata S. Patil, Wei Zou, et al. · PLoS ONE · 10
PDF
Abstract P3-06-05: Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
2015 · Denise M Wolf, Christina Yau, et al. · Cancer Research · 3
Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process.
2014 · Meredith B. Buxton, Kelsey Natsuhara, et al. · Journal of Clinical Oncology · 3
Abstract 4055: Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung cancer patients responding to atezolizumab treatment
2019 · Mahesh Yadav, Michael Fehlings, et al. · Cancer Research
Additional file 6: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Fehlings, Michael, Suchit Jhunjhunwala, et al. · Figshare
Additional file 5: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Fehlings, Michael, Suchit Jhunjhunwala, et al. · Figshare
Additional file 7: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Fehlings, Michael, Suchit Jhunjhunwala, et al. · Figshare
Additional file 8: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Fehlings, Michael, Suchit Jhunjhunwala, et al. · Figshare
Additional file 4: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Fehlings, Michael, Suchit Jhunjhunwala, et al. · Figshare
Additional file 9: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
2019 · Fehlings, Michael, Suchit Jhunjhunwala, et al. · Figshare
Abstract 5707: On-treatment changes in CRP as a surrogate for overall survival for atezolizumab benefit in 2nd line NSCLC
2018 · Namrata Patil, Wei Zou, et al. · Cancer Research
Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
2015 · Denise M Wolf, Christina Yau, et al. · Cancer Research
Abstract P3-06-15: Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial
2015 · Julia D Wulfkuhle, Christina Yau, et al. · Cancer Research
Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
2015 · Christina Yau, Denise M Wolf, et al. · Cancer Research
Works count: 21
Citation count: 422
H-index: 4
I10-index: 4
Year
Topic
Type